Immune Globulin Therapy Has No Benefit for Neonatal Sepsis

Nonsignificant differences seen for outcomes with immune globulin and placebo in neonatal sepsis

WEDNESDAY, Sept. 28 (HealthDay News) -- Infants with suspected or proven sepsis treated with intravenous immune globulin have no significant difference in outcomes compared to those receiving a placebo, according to a study published in the Sept. 29 issue of the New England Journal of Medicine.

Peter Brocklehurst, M.B., Ch.B., from the University of Oxford in the United Kingdom, and colleagues from the International Neonatal Immunotherapy Study Collaborative Group examined the efficacy of adjunctive therapy with immune globulin in 3,493 newborn infants receiving antibiotics for suspected or proven sepsis. A total of 1,759 infants received two infusions of human nonspecific polyvalent immunoglobulin G immune globulin (500 mg per kilogram of body weight) and 1,734 received a matching placebo 48 hours apart. Death or major disability at the age of 2 years was the primary outcome.

The investigators identified no significant difference in the primary outcome rates between the groups (39 percent each for those receiving immune globulin or placebo). The differences in the incidence of subsequent sepsis episodes and other secondary outcomes were also found to be nonsignificant. No significant differences were observed in the rates of major or non-major disability or adverse events in the follow-up of 2-year-old infants.

"Therapy with intravenous immune globulin had no effect on the outcomes of suspected or proven neonatal sepsis," the authors write.

Full Text (subscription or payment may be required)

Copyright © 2011 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

What internal motivators drive RNs to pursue a BSN?
Nursing2014 , October 2014
Free access will expire on November 24, 2014.


Breast Cancer Risk Assessment in Primary Care
MCN, The American Journal of Maternal/Child Nursing, September/October 2014
Free access will expire on November 10, 2014.


Nurses spurring innovation
Nursing Management, October 2014
Free access will expire on November 10, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events